loading
Schlusskurs vom Vortag:
$46.40
Offen:
$46.02
24-Stunden-Volumen:
66,646
Relative Volume:
0.09
Marktkapitalisierung:
$4.30B
Einnahmen:
$522.75M
Nettoeinkommen (Verlust:
$-558.99M
KGV:
-5.2235
EPS:
-8.97
Netto-Cashflow:
$-492.48M
1W Leistung:
-1.70%
1M Leistung:
-14.01%
6M Leistung:
+15.40%
1J Leistung:
+20.57%
1-Tages-Spanne:
Value
$45.91
$46.88
1-Wochen-Bereich:
Value
$43.04
$48.11
52-Wochen-Spanne:
Value
$37.02
$60.37

Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile

Name
Firmenname
Ultragenyx Pharmaceutical Inc
Name
Telefon
415-483-8800
Name
Adresse
60 LEVERONI COURT, NOVATO, CA
Name
Mitarbeiter
1,276
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-05
Name
Neueste SEC-Einreichungen
Name
RARE's Discussions on Twitter

Vergleichen Sie RARE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
RARE 46.86 4.30B 522.75M -558.99M -492.48M -8.97
VRTX 447.00 115.74B 10.63B -479.80M -1.35B 13.33
REGN 742.11 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 588.93 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.68 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.55 24.49B 3.30B -501.07M 1.03B 11.54

Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-12-08 Eingeleitet Wells Fargo Overweight
2023-06-14 Fortgesetzt Credit Suisse Outperform
2023-06-06 Hochstufung Evercore ISI In-line → Outperform
2023-04-26 Eingeleitet Cantor Fitzgerald Overweight
2023-01-18 Fortgesetzt Canaccord Genuity Buy
2022-12-30 Fortgesetzt H.C. Wainwright Buy
2022-11-03 Hochstufung Robert W. Baird Neutral → Outperform
2022-10-13 Hochstufung Guggenheim Neutral → Buy
2022-08-01 Herabstufung Evercore ISI Outperform → In-line
2022-03-16 Hochstufung Credit Suisse Neutral → Outperform
2022-02-11 Hochstufung JP Morgan Neutral → Overweight
2021-09-30 Eingeleitet H.C. Wainwright Buy
2021-08-19 Eingeleitet UBS Sell
2021-07-15 Eingeleitet Guggenheim Neutral
2021-06-29 Hochstufung BofA Securities Neutral → Buy
2021-06-04 Fortgesetzt Robert W. Baird Neutral
2021-05-06 Hochstufung Citigroup Neutral → Buy
2021-05-06 Hochstufung Evercore ISI In-line → Outperform
2021-04-26 Fortgesetzt Credit Suisse Neutral
2021-03-02 Fortgesetzt Stifel Buy
2021-02-12 Herabstufung JP Morgan Overweight → Neutral
2020-12-07 Herabstufung Wedbush Outperform → Neutral
2020-11-24 Fortgesetzt Evercore ISI In-line
2020-11-12 Herabstufung BofA Securities Buy → Neutral
2019-08-02 Fortgesetzt Wedbush Outperform
2019-03-27 Hochstufung Morgan Stanley Equal-Weight → Overweight
2019-02-22 Fortgesetzt Raymond James Outperform
2019-01-02 Herabstufung Raymond James Outperform → Mkt Perform
2018-11-08 Hochstufung Citigroup Sell → Neutral
2018-09-10 Eingeleitet Morgan Stanley Equal-Weight
2018-06-21 Herabstufung Credit Suisse Outperform → Neutral
2018-05-11 Hochstufung Barclays Equal Weight → Overweight
2018-05-10 Eingeleitet Goldman Neutral
2018-04-18 Hochstufung SunTrust Hold → Buy
2018-03-22 Fortgesetzt Piper Jaffray Overweight
2018-02-21 Bestätigt Stifel Buy
2018-01-22 Hochstufung Evercore ISI In-line → Outperform
2018-01-18 Eingeleitet Credit Suisse Outperform
2017-12-05 Bestätigt Barclays Equal Weight
2017-12-04 Hochstufung Jefferies Hold → Buy
2017-09-14 Hochstufung Wedbush Neutral → Outperform
Alle ansehen

Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten

pulisher
Nov 20, 2024

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 20, 2024
pulisher
Nov 20, 2024

Ultragenyx Grants 20,820 RSUs to New Officers in Four-Year Vesting Plan | RARE Stock News - StockTitan

Nov 20, 2024
pulisher
Nov 20, 2024

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat

Nov 20, 2024
pulisher
Nov 18, 2024

State of New Jersey Common Pension Fund D Has $1.93 Million Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Nov 18, 2024
pulisher
Nov 15, 2024

Osteogenesis Imperfecta Treatment Market 2024-2031: Global - openPR

Nov 15, 2024
pulisher
Nov 14, 2024

How To Trade (RARE) - Stock Traders Daily

Nov 14, 2024
pulisher
Nov 14, 2024

RTW INVESTMENTS, LP Adjusts Stake in Ultragenyx Pharmaceutical I - GuruFocus.com

Nov 14, 2024
pulisher
Nov 13, 2024

Ultragenyx Pharmaceutical's SWOT analysis: pipeline progress boosts rare disease stock - Investing.com

Nov 13, 2024
pulisher
Nov 12, 2024

Ultragenyx posts trial data backing Phase 3 design for Angelman syndrome therapy - MSN

Nov 12, 2024
pulisher
Nov 12, 2024

Ultragenyx Pharmaceutical (NASDAQ:RARE) Receives Buy Rating from Canaccord Genuity Group - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Ultragenyx: Ready For More Growth After Q3 Earnings Beat (NASDAQ:RARE) - Seeking Alpha

Nov 12, 2024
pulisher
Nov 12, 2024

Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Nov 12, 2024
pulisher
Nov 11, 2024

Research Analysts Offer Predictions for RARE FY2024 Earnings - MarketBeat

Nov 11, 2024
pulisher
Nov 10, 2024

Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates - MSN

Nov 10, 2024
pulisher
Nov 09, 2024

Ultragenyx posts data for Angelman syndrome therapy (RARE:NASDAQ) - Seeking Alpha

Nov 09, 2024
pulisher
Nov 09, 2024

Ultragenyx Presents Positive Update on GTX-102 Angelman - GlobeNewswire

Nov 09, 2024
pulisher
Nov 09, 2024

Ultragenyx's Angelman Treatment Shows 80% Patient Improvement in Phase 1/2 Trial | RARE Stock News - StockTitan

Nov 09, 2024
pulisher
Nov 08, 2024

What is Wedbush's Estimate for RARE FY2024 Earnings? - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Leerink Partnrs Has Negative Outlook of RARE FY2024 Earnings - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

What is HC Wainwright's Estimate for RARE FY2024 Earnings? - MarketBeat

Nov 08, 2024
pulisher
Nov 07, 2024

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 07, 2024
pulisher
Nov 07, 2024

What is HC Wainwright's Estimate for RARE Q1 Earnings? - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Ultragenyx Pharmaceutical Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St

Nov 07, 2024
pulisher
Nov 06, 2024

Ultragenyx Pharmaceutical's (RARE) Overweight Rating Reiterated at Cantor Fitzgerald - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Ultragenyx Pharma stock target raised, retains buy on strong revenue growth - Investing.com India

Nov 06, 2024
pulisher
Nov 06, 2024

HC Wainwright Boosts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $95.00 - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Ultragenyx Pharma stock target raised, retains buy on strong revenue growth By Investing.com - Investing.com South Africa

Nov 06, 2024
pulisher
Nov 06, 2024

Evaluating Ultragenyx Pharmaceutical: Insights From 7 Financial Analysts - Benzinga

Nov 06, 2024
pulisher
Nov 06, 2024

International Assets Investment Management LLC Boosts Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Ultragenyx: Excellent Company, Lackluster Stock (NASDAQ:RARE) - Seeking Alpha

Nov 06, 2024
pulisher
Nov 06, 2024

Ultragenyx Pharmaceutical Inc (RARE) Q3 2024 Earnings Call Highlights: Robust Revenue Growth ... - Yahoo Finance

Nov 06, 2024
pulisher
Nov 05, 2024

Ultragenyx Reports Strong Q3 Growth and Milestones - TipRanks

Nov 05, 2024
pulisher
Nov 05, 2024

Ultragenyx Pharmaceutical reports an over 40% increase in Q3 revenue - North Bay Business Journal

Nov 05, 2024
pulisher
Nov 05, 2024

Ultragenyx Pharmaceutical Q3 2024 Earnings Preview - MSN

Nov 05, 2024
pulisher
Nov 05, 2024

Ultragenyx Pharmaceutical Inc (RARE) Q3 2024 Earnings: Revenue S - GuruFocus.com

Nov 05, 2024
pulisher
Nov 05, 2024

Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Nov 05, 2024
pulisher
Nov 05, 2024

Ultragenyx: Q3 Earnings Snapshot - San Francisco Chronicle

Nov 05, 2024
pulisher
Nov 05, 2024

Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update - The Manila Times

Nov 05, 2024
pulisher
Nov 05, 2024

Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Full Year 2024 - Marketscreener.com

Nov 05, 2024
pulisher
Nov 05, 2024

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by Wealth Enhancement Advisory Services LLC - MarketBeat

Nov 05, 2024
pulisher
Nov 04, 2024

A Look Ahead: Ultragenyx Pharmaceutical's Earnings Forecast - Benzinga

Nov 04, 2024
pulisher
Nov 03, 2024

Trend Tracker for (RARE) - Stock Traders Daily

Nov 03, 2024
pulisher
Nov 03, 2024

Emerald Advisers LLC Raises Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Nov 03, 2024
pulisher
Nov 02, 2024

abrdn plc Sells 31,441 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Nov 02, 2024
pulisher
Nov 01, 2024

RAREUltragenyx Pharmaceutical Inc. Latest Stock News & Market Updates - StockTitan

Nov 01, 2024
pulisher
Nov 01, 2024

What Makes Ultragenyx Pharmaceutical (RARE) an Exciting Investment Opportunity? - Insider Monkey

Nov 01, 2024
pulisher
Oct 31, 2024

Oversold Conditions For Ultragenyx Pharmaceutical (RARE) - Nasdaq

Oct 31, 2024
pulisher
Oct 31, 2024

Pinnacle Associates Ltd. Has $6.63 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Oct 31, 2024
pulisher
Oct 30, 2024

Ultragenyx Pharmaceutical (RARE) to Release Earnings on Tuesday - MarketBeat

Oct 30, 2024
pulisher
Oct 30, 2024

Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update - The Manila Times

Oct 30, 2024

Finanzdaten der Ultragenyx Pharmaceutical Inc-Aktie (RARE)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):